Roivant Sciences Ltd.
ROIV
$20.81
-$0.06-0.29%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -373.97M | -490.63M | -171.98M | -116.62M | 4.81B |
| Total Depreciation and Amortization | 12.13M | 13.12M | 14.07M | 19.70M | 20.28M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -359.31M | -328.02M | -604.50M | -582.85M | -5.59B |
| Change in Net Operating Assets | -48.71M | -45.48M | -77.05M | -95.58M | -21.28M |
| Cash from Operations | -769.86M | -851.01M | -839.45M | -775.34M | -778.54M |
| Capital Expenditure | -14.52M | -7.67M | -4.60M | -4.14M | -2.67M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 229.36M | 339.75M | 339.75M | 264.02M | 5.34B |
| Other Investing Activities | 348.13M | -3.18B | -2.10B | -3.09B | -3.39B |
| Cash from Investing | 562.97M | -2.85B | -1.77B | -2.83B | 1.95B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -49.09M | -50.92M | -52.75M | -60.42M | -18.99M |
| Issuance of Common Stock | 140.21M | 78.41M | 50.63M | 41.31M | 22.08M |
| Repurchase of Common Stock | -779.19M | -887.22M | -1.33B | -1.06B | -807.49M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 112.78M | 112.78M | 112.78M | 0.00 | 238.73M |
| Cash from Financing | -575.29M | -746.95M | -1.22B | -1.08B | -565.68M |
| Foreign Exchange rate Adjustments | 465.00K | 4.30M | 747.00K | 381.00K | 4.49M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -781.71M | -4.44B | -3.82B | -4.68B | 605.68M |